Top

Supportive Care in Cancer

Published in:

01-02-2012 | Original Article

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Authors: Dildar Bahar Genc, Cengiz Canpolat, Su Gulsun Berrak

Published in: Supportive Care in Cancer | Issue 2/2012

Abstract

Purpose

The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively.

Method

Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated.

Results

CHR were observed in 20 (40%) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1–41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75%.

Conclusions

This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.

Aquino VM, Fort DW, Kamen BA (1999) Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neurooncol 41:255–259PubMedCrossRef

Ater J, Holmes E, Zhou T, Mazewski C, Roberts W, Booth T, Ettinger A, Freyer D, Jakacki R, Kadota R, Lazarus K, Pearce J, Pollack I, Prados M, Sposto R, Vezina G, Wisoff J, Yates A, Packer R (2006) Treatment of young children with progressive or symptomatic unresectable low-grade glioma with chemotherapy: preliminary report from the Children’s Oncology Group (COG) phase 3 protocol A9952. Neuro Oncol 8:465–465

Bourgeois FT, Mandl KD, Valim C, Shannon MW (2009) Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 124:e744–e750PubMedCrossRef

Broome CB, Schiff RI, Friedman HS (1996) Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 26:105–110PubMedCrossRef

Castells M (2007) Drug desensitization in oncology: chemotherapy agents and monoclonal antibodies. In: Pichler WJ (ed) Drug hypersensitivity. Karger, Bern, pp 413–425CrossRef

Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574–580PubMedCrossRef

Chang SM, Fryberger S, Crouse V, Tilford D, Prados MD (1995) Carboplatin hypersensitivity in children. A report of five patients with brain tumors. Cancer 75:1171–1175PubMedCrossRef

Choi J, Harnett P, Fulcher DA (2004) Carboplatin desensitization. Ann Allergy Asthma Immunol 93(2):137–141

Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute—Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935PubMedCrossRef

10.

Demaerel P, de Ruyter N, Casteels I, Renard M, Uyttebroeck A, van Gool S (2002) Visual pathway glioma in children treated with chemotherapy. Eur J Paediatr Neurol 6:207–212PubMedCrossRef

11.

Gnekow AK, Kortmann RD, Pietsch T, Emser A (2004) Low grade chiasmatic–hypothalamic glioma—carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy—report from the multicenter treatment study for children and adolescents with a low grade glioma—HIT-LGG 1996—of the Society of Pediatric Oncology and Hematology (GPOH). Klin Pädiatr 216:331–342PubMedCrossRef

12.

Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS (2002) Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 20(13):2951–2958PubMedCrossRef

13.

Heath JA, Turner CD, Poussaint TY, Scott RM, Goumnerova L, Kieran MW (2003) Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana–Farber experience. Pediatr Hematol Oncol 20:497–504PubMedCrossRef

14.

Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, Huang A, Bouffet E (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103:2636–2642PubMedCrossRef

15.

Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E (2008) Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian pediatric brain tumor consortium experience. Cancer 112:892–899PubMedCrossRef

16.

Lazzareschi I, Ruggiero A, Riccardi R, Attina G, Colosimo C, Lasorella A (2002) Hypersensitivity reactions to carboplatin in children. J Neurooncol 58:33–37PubMedCrossRef

17.

Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, James HE, Duffner PK, Kun LE (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213–220PubMed

18.

Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010:pii:207084;1–11

19.

Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F (2010) A lower-dose, lower-toxicity cisplatin–etoposide regimen for childhood progressive low-grade glioma. J Neurooncol 100:65–71PubMedCrossRef

20.

Menniti-Ippolito G, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L (2000) Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet 355:1613–1614PubMedCrossRef

21.

Morgan M, Bowers DC, Gruchalla RS, Khan DA (2004) Safety and efficacy of repeated monthly carboplatin desensitization. J Allergy Clin Immunol 114:974–975PubMedCrossRef

22.

Ogle SK, Rose MM, Wildes CT (2002) Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1 and hypersensitivity reactions in an outpatient oncology clinic. J Pediatr Oncol Nurs 19:122–126PubMedCrossRef

23.

Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747–754PubMedCrossRef

24.

Packer RJ, MacDonald T, Vezina G (2008) Central nervous system tumors. Pediatr Clin N Am 55:121–145, xiCrossRef

25.

Perilongo G (2005) Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J Neurooncol 75:301–307PubMedCrossRef

26.

Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129–133PubMedCrossRef

27.

Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M (2003) Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89:429–433PubMedCrossRef

28.

Schiavetti A, Varrasso G, Maurizi P, Castello MA (1999) Hypersensitivity to carboplatin in children. Med Pediatr Oncol 32:183–185PubMedCrossRef

29.

Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ (2007) Allergic reactions to E. coli l-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children’s Oncology Group study. J Pediatr Hematol Oncol 29:627–632PubMedCrossRef

30.

Wiesner AZF, Lauener RP, Grotzer MA (2004) Hypersensitivity to carboplatin in children with low-grade glioma. J Ped Neurol 2:151–155

31.

Yu DY, Dahl GV, Shames RS, Fisher PG (2001) Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol 23(6):349–352

Title: Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma
Authors: Dildar Bahar Genc
Cengiz Canpolat
Su Gulsun Berrak
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 2/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1123-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2012

A bridge between cultures: interpreters’ perspectives of consultations with migrant oncology patients

Clinical exercise interventions in prostate cancer patients—a systematic review of randomized controlled trials

Antibiotics in palliative medicine—results from a prospective epidemiological investigation from the HOPE survey

Managing chronic pain: results from an open-label study using MC5-A Calmare® device

Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998–2008): Diverse and impactful

Weight loss in cancer patients: a plea for a better awareness of the issue

Keynote webinar | Spotlight on antibody–drug conjugates in cancer